Search





Search





Markets
/
Stocks
/
nasdaq-eq
/

Equillium Inc

Add to Watchlist

2.180USD

-0.410-15.83%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

137.83MMarket Cap

LossP/E TTM



Equillium Inc

2.180

-0.410-15.83%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Equillium Inc

Currency: USD Updated: 2026-05-15

Key Insights

Equillium Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 82 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.14.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Equillium Inc's Score

Industry at a Glance

Industry Ranking

82 / 382

Overall Ranking

199 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Equillium Inc Highlights

StrengthsRisks

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Its EQ302 is a selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. EQ101 is a clinical-stage, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which are key disease-driving, clinically validated cytokine targets to address unmet needs across a range of immuno-inflammatory indications. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level, targeting pathogenic cytokine redundancies and synergies. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the modulation of effector T cells.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -10.75, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.51M shares, increasing 18.02% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 733.23K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

7.143

Target Price

+175.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Equillium Inc is 7.40, ranking 90 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.38

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.24

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Equillium Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Equillium Inc is 6.92, ranking 191 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -10.75, which is -97.18% below the recent high of -0.30 and -18.81% above the recent low of -12.77.

Score

Industry at a Glance

Previous score

6.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 82/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Equillium Inc is 8.40, ranking 127 out of 382 in the Biotechnology & Medical Research industry. The average price target is 2.50, with a high of 4.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

8.75

Change

-0.35

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

7.143

Target Price

+175.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Equillium Inc

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

argenx SE

ARGX

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Equillium Inc is 7.47, ranking 63 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.61 and the support level at 1.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.78

Change

-2.31

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.039

Buy

RSI(14)

51.581

Neutral

STOCH(KDJ)(9,3,3)

57.387

Sell

ATR(14)

0.201

Low Volatility

CCI(14)

103.794

Buy

Williams %R

68.657

Sell

TRIX(12,20)

0.539

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

2.320

Sell

MA10

2.219

Sell

MA20

2.165

Buy

MA50

2.067

Buy

MA100

1.772

Buy

MA200

1.523

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Equillium Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 62.48%, representing a quarter-over-quarter increase of 404.43%. The largest institutional shareholder is James Simons, holding a total of 733.23K shares, representing 1.16% of shares outstanding, with 53.70% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Janus Henderson Investors

5.86M

Adar1 Capital Management LLC

5.61M

+0.86%

Adage Capital Management, L.P.

5.33M

Decheng Capital LLC

4.45M

Steel (Bruce D)

3.71M

Bradbury (Daniel M)

3.71M

Woodline Partners LP

3.50M

-0.22%

abrdn Inc.

2.37M

+523.59%

RA Capital Management, LP

3.10M

Balyasny Asset Management LP

2.08M

+3.62%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Equillium Inc is 1.59, ranking 287 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.70. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.